
Alta Partners
Description
Alta Partners is a well-established venture capital firm with a dedicated focus on the healthcare and life sciences sector. Founded in 1996 and headquartered in San Francisco, California, the firm has built a reputation for identifying and nurturing innovative companies across biotechnology, medical devices, diagnostics, and healthcare services. With a long track record spanning over two decades, Alta Partners has consistently aimed to support companies that address significant unmet medical needs and improve patient outcomes.
The firm's investment strategy centers on early to growth-stage companies, typically participating in Series A and B rounds, though they may also engage in select seed investments for highly promising ventures. Alta Partners is known for its deep industry expertise, leveraging its team's scientific, medical, and operational backgrounds to provide strategic guidance to its portfolio companies. Initial investments from Alta Partners typically range from $5 million to $20 million, reflecting their commitment to providing substantial capital to fuel development and commercialization efforts.
Alta Partners has demonstrated significant financial strength, having raised over $2 billion in capital across numerous funds since its inception. For instance, their Alta Partners VIII fund, closed in 2008, secured $300 million, underscoring their capacity for substantial investments. Their portfolio includes a diverse array of companies that have gone on to achieve successful clinical milestones, regulatory approvals, and strategic exits, contributing significantly to advancements in healthcare. The firm's consistent focus and substantial capital base position it as a key player in the specialized healthcare venture capital landscape.
Investor Profile
Alta Partners has backed more than 264 startups, with 3 new investments in the last 12 months alone. The firm has led 55 rounds, about 21% of its total and boasts 86 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series A, Series C rounds (top funding stages).
- Majority of deals are located in United States, Denmark, The Netherlands.
- Strong thematic focus on Biotechnology, Health Care, Medical.
- Typical check size: $5M – $20M.
Stage Focus
- Series B (24%)
- Series A (19%)
- Series C (18%)
- Series Unknown (16%)
- Series D (13%)
- Series E (5%)
- Post Ipo Equity (3%)
- Debt Financing (1%)
- Private Equity (1%)
- Series F (1%)
Country Focus
- United States (89%)
- Denmark (2%)
- The Netherlands (2%)
- United Kingdom (2%)
- France (1%)
- Sweden (1%)
- Belgium (1%)
Industry Focus
- Biotechnology
- Health Care
- Medical
- Therapeutics
- Pharmaceutical
- Medical Device
- Biopharma
- Health Diagnostics
- Genetics
- Life Science
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.